DOC Forensic analysis

Trading Setup & Entry Strategy

• >Entry Zone: $18.80 – $19.10. Strategy: Accumulate 30% at $19.10; scale in the remaining 70% if price dips to the $18.80 support cluster (near the 50-day SMA inflection point).
• >Stop Loss: $17.85 (HARD). Reasoning: Positioned below the confluence of the 50-day and 200-day SMAs. A breakdown below this level invalidates the bullish thesis.
• >Take Profit: Target 1 at $20.50 (50% trim); Target 2 at $21.20 (Upper Bollinger Band resistance).
• >Risk/Reward: 1:2.4.

Recent Material Events (8-K Analysis)

• >Janus Living IPO (March 2026): A transformative event. Healthpeak retains 81.6% voting/economic control and consolidates Janus. The IPO unlocked liquidity, facilitating the reduction of mortgage debt and reinforcing the balance sheet.

Insider Trading Activity

• >High frequency of Form 4 activity in early May 2026. While specific details were summarized as 'FORM 4', the timing aligns with the earnings beat and guidance raise, suggesting positive sentiment among management.

Financial Health & Forensics

• >Revenue Quality: Stable rental revenue ($538M) with significant growth in resident fees ($200M) driven by the RIDEA transition.
• >Balance Sheet: Solid liquidity with $1.17B in cash. Debt profile remains manageable, though commercial paper usage ($1.75B) requires ongoing monitoring of short-term interest rate exposure.

Valuation & Technical Analysis

• >Technical Reconciliation: Currently in a BULLISH_CROSSING phase with the price sitting well above the 50-day ($17.32) and 200-day ($17.49) SMAs. With an RSI of 67.33, the stock is approaching overbought territory but remains supported by a strong MACD histogram (+0.1496).
• >Reverse DCF: The market is pricing in steady growth, likely mid-to-high single digits, which is supported by the 2026 guidance raise.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Position Size: 4% of portfolio.
• >Strategy: Capitalize on post-earnings momentum. Avoid chasing at $19.30; wait for the daily consolidation/pullback to the $19.00 level to improve R/R.

One-Liner Thesis: Healthpeak's successful Janus Living IPO and subsequent earnings beat provide a strong fundamental floor, while the current 'Bullish Crossing' technical setup suggests room for a test of the $21.00 handle.